Evidence map›Paper›PMID 42779931›Full record

ArticleResearch square2026

Self-adjuvanting Ebola virus-like particles that incorporate a cellular interferon-inducing domain.

Naveen Thakur, Lin Wang, Tshidi Tsibane, Jesus A Silvas, Viktoriya Borisevich, Rachel O'Toole, Jasmine Martinez, Thomas W Geisbert, Robert W Cross, Christopher F Basler and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Naveen ThakurDept. Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lin WangCenter for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Tshidi TsibaneCenter for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Jesus A SilvasCenter for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Viktoriya BorisevichGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Rachel O'TooleGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Jasmine MartinezGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Thomas W GeisbertGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Robert W CrossGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Christopher F BaslerDept. Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
JoAnn M TufarielloDept. Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

Virology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI Gaya K. Amarasinghe · 2016 to 2026
$30.2M
Intrinsically-enhanced Ebola and Marburg virus like particles for increased potency and immune memoryR21AI146682 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI TUFARIELLO, JOANN M · 2020 to 2021
$471k
NIAID NIH HHS P01 AI120943NIAID NIH HHS R21 AI146682
6 · The paper itself

Abstract

Ebola virus-like particle (EBOV VLP) vaccines composed of glycoprotein (GP), matrix protein VP40, and nucleoprotein (NP) typically require multiple adjuvanted doses to elicit protection. To enhance immunogenicity and mimic live virus infection, retinoic acid-inducible gene I (RIG-I) N-terminal CARD domains (2CARD), which can trigger type I interferon (IFN) production, were fused to the NP C-terminal domain (NP

Identifiers

PMID42779931
PMCPMC13596661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.